$CSTL· News ·

Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders

Castle Biosciences, Inc. Common Stock · SERVICES-MEDICAL LABORATORIES · Now $20.97

-3.2% in 3d after detection

Post-detection moves

1h
1d
+3.1%
3d
-3.2%
7d
+0.4%
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS